AS250 inhibitors are a class of chemical compounds known for their ability to specifically inhibit the activity of the AS250 protein or enzyme. These inhibitors typically function by binding to the active site or allosteric sites of AS250, thereby preventing its normal biochemical function. AS250, like many enzymes or proteins within a biological system, plays a critical role in various cellular processes, and its inhibition can disrupt or modulate these processes. AS250 inhibitors are designed to offer specificity in targeting the AS250 protein without significantly affecting other proteins, thus providing researchers with a valuable tool to study the role of AS250 in various pathways.
The structure of AS250 inhibitors is often characterized by a core chemical scaffold that interacts with key residues within the AS250 active site. This scaffold is frequently optimized through modifications to enhance binding affinity, stability, and selectivity. Depending on the inhibitor, different chemical groups may be added or altered to improve solubility, reduce off-target effects, or enhance interaction with particular binding pockets on AS250. Research on AS250 inhibitors often focuses on their physicochemical properties, such as their molecular weight, polarity, and hydrophobicity, which influence their bioavailability and interaction with AS250. These compounds are frequently utilized in biochemical assays, cellular experiments, and other research settings to investigate the fundamental mechanisms controlled by AS250, shedding light on its role in cellular regulation, signal transduction, or metabolic processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts Golgi apparatus function, potentially affecting Ral-mediated signaling and AS250. | ||||||
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
Inhibits RhoA-mediated signaling, possibly impacting pathways connected with AS250. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
A c-Raf kinase inhibitor, might indirectly influence AS250-associated signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, could impact signaling pathways involving AS250. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, potentially affecting signaling pathways related to AS250's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Another MEK inhibitor, might influence downstream signaling pathways associated with AS250. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Inhibits HMG-CoA reductase, could indirectly affect Ral GTPase signaling and AS250. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A tyrosine kinase inhibitor, might indirectly influence signaling pathways involving AS250. | ||||||